NASDAQ:TSHA | Free Cash Flow | Taysha Gene Therapies, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2020-03-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$40.88M$24,000.00-$40.9M
2025-12-31-$26.72M$250,000.00-$26.97M
2025-03-31-$22.02M$378,000.00-$22.4M
2024-12-31-$18.31M-$2,000.00-$18.31M
2024-03-31-$19.8M$140,000.00-$19.94M
2023-12-31-$16.12M$17,000.00-$16.13M-33.79%
2023-03-31-$20.19M$3.9M-$24.09M
2022-12-31$14.71M$2.31M$12.4M
2022-03-31-$40.94M$8.43M-$49.37M
2021-12-31-$40.26M$8.27M-$48.53M
2021-03-31-$22.04M$534,000.00-$22.57M
2020-12-31-$19.85M$51,000.00-$19.9M
2020-03-31-$1.7M$0.00-$1.7M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$93.09M$738,000.00-$93.83M
2024-12-31-$81.23M$374,000.00-$81.6M
2023-12-31-$73.02M$3.87M-$76.89M
2022-12-31-$88.39M$20.62M-$109.01M
2021-12-31-$117.04M$15.3M-$132.35M
2020-12-31-$30.73M$82,000.00-$30.81M

Research interface only. Not investment advice. Prices are a checked-in snapshot, not live quotes.